Literature DB >> 140758

Reversible dysfunction of T-lymphocytes in common variable immunodeficiency.

W H Marshall, P W Allderdice, H W Edstrom, R M Newton, E Pike.   

Abstract

A 30-year-old man with recurrent sinopulmonary infections, eventually fatal, was found to have common variable immunodeficiency. In addition to low serum immunoglobulin concentrations he also had lymphopenia and cell-mediated immunodeficiency as shown by cutaneous anergy and a poor lymphocyte response to phytohemagglutinin (PHA) in vitro. However, intradermal injection of PHA produced a vigorous cutaneous response, showing that some cell-mediated responsiveness remained. The responsiveness of his lymphocytes to PHA was restored towards normal (confirmed by chromosome studies) by the addition of a small number of normal leukocytes to cultures; thus a reversible functional defect in his T-lymphocytes was revealed. Experiments indicated that the defect was cellular and not due to serum factors and it was concluded that normal leukocytes restored a missing factor to the patient's T-lymphocytes. Although counts of macrophage precursor cells in the bloodstream were low, thus contributing to the immunodeficiency, this could not have caused the reduced PHA response. Several relatives of this patient had lymphoma; two cousins had common variable immunodeficiency.

Entities:  

Mesh:

Year:  1977        PMID: 140758      PMCID: PMC1879271     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  15 in total

1.  Counts and characteristics of macrophage precursors in human peripheral blood.

Authors:  G Krikorian; W H Marshall; S Simmons; F Stratton
Journal:  Cell Immunol       Date:  1975-09       Impact factor: 4.868

2.  PRIMARY "ACQUIRED" HYPOGAMMAGLOBULINEMIA; CLINICAL AND GENETIC ASPECTS OF NINE CASES.

Authors:  F A WOLLHEIM; S BELFRAGE; C COESTER; H LINDHOLM
Journal:  Acta Med Scand       Date:  1964-07

3.  THE ORIGIN OF MACROPHAGES FROM BONE MARROW IN THE RAT.

Authors:  A VOLKMAN; J L GOWANS
Journal:  Br J Exp Pathol       Date:  1965-02

4.  Quantitative measurements of T- and B-cell function in "variable" primary hypogammaglobulinaemia: evidence for a consistent B-cell defect.

Authors:  E G de la Concha; G Oldham; A D Webster; G L Asherson; T A Platts-Mills
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

5.  Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

Authors:  T A Waldmann; M Durm; S Broder; M Blackman; R M Blaese; W Strober
Journal:  Lancet       Date:  1974-09-14       Impact factor: 79.321

6.  Agammaglobulinaemia with B lymphocytes. Specific defect of plasma-cell differentiation.

Authors:  M D Cooper; A R Lawton; D E Bockman
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

7.  Lymphocyte transformation and mitosis in vitro initiated by homologous macrophages. An improved method for histocompatibility testing.

Authors:  W H Marshall; S J Rigo; S Melman
Journal:  Lancet       Date:  1966-04-02       Impact factor: 79.321

8.  Immunoglobulin synthesis in vitro by lymphocytes from patients with immune deficiency: requirements for a special serum factor.

Authors:  P Wernet; F P Siegal; H Dickler; S Fu; H G Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1974-02       Impact factor: 11.205

9.  Attempt to restore lymphocytes with defective T-cell function by mixing with normal cells in vitro.

Authors:  W H Marshall; R M Newton; W Sprague
Journal:  Can Med Assoc J       Date:  1973-06-02       Impact factor: 8.262

10.  Differentiation capacity of cultured B lymphocytes from immunodeficient patients.

Authors:  L Y Wu; A R Lawton; M D Cooper
Journal:  J Clin Invest       Date:  1973-12       Impact factor: 14.808

View more
  1 in total

1.  Defective cellular immune response in vitro in common variable immunodeficiency.

Authors:  S Cunningham-Rundles; C Cunningham-Rundles; F P Siegal; S Gupta; E M Smithwick; C Kosloff; R A Good
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.